Fispemifene: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 29: | Line 29: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
<gallery> | |||
File:Fispemifene.svg|Fispemifene | |||
</gallery> | |||
Latest revision as of 21:53, 16 March 2025
Fispemifene is a synthetic steroid and selective estrogen receptor modulator (SERM) that is used in the treatment of male hypogonadism and osteoporosis in men. It is a nonsteroidal antiestrogen that is similar in structure and action to tamoxifen and raloxifene.
Mechanism of Action[edit]
Fispemifene acts as an antagonist at estrogen receptors in some tissues and as an agonist in others. In the prostate and breast, it acts as an antagonist, inhibiting the growth-promoting effects of estrogen. In bone and lipid metabolism, it acts as an agonist, mimicking the beneficial effects of estrogen.
Clinical Use[edit]
Fispemifene is used in the treatment of male hypogonadism, a condition characterized by low levels of testosterone and symptoms such as fatigue, depression, and sexual dysfunction. It is also used in the treatment of osteoporosis in men, a condition characterized by low bone mass and increased risk of bone fractures.
Side Effects[edit]
Common side effects of fispemifene include hot flashes, nausea, and vomiting. Less common side effects include breast pain, joint pain, and insomnia.
Pharmacokinetics[edit]
Fispemifene is well absorbed after oral administration and is extensively metabolized in the liver. It has a half-life of approximately 8 hours and is excreted primarily in the urine.
See Also[edit]
-
Fispemifene
